On this week’s episode of Biotech Hangout, guest Matthew Gline (CEO of Roivant) joins hosts Brad Loncar, Tim Opler and Brian Skorney to discuss Biogen’s heavy news week, including their acquisition of Reata for $6.5 billion, their decision to cut 1,000 jobs by 2025 and their quiet stance regarding their upcoming PDUFA date to treat PPD and MDD in partnership with Sage. The hosts also cover other layoff and leadership changes, including the resignation of FibroGen’s CEO and layoffs from Infinity and Mersana. The group also touches on the $2.8 billion hypertension deal between Roche and Alnylam and the impact this deal could have on patients. Additionally, they discuss Gilead being accused of slow-walking the development of a new version of an HIV therapy to extend their patent protection, British billionaire Joe Lewis being charged with insider trading and the impact that poor data readouts had on Stoke Therapeutics’, Gilead’s and Kodiak’s shares. *This episode aired on July 28, 2023*